Engagement
3-month build & operate
×
BIOCREATIVE
×
BIOCREATIVE
You need a complete commercial infrastructure that understands life sciences and can execute at volume without burning founder time. We build it custom, we operate it alongside you, and the system you own today is engineered to grow with Trell into every market you enter next. Biotech first. Built to scale.
A short recap of the operating picture you laid out — so the rest of this document is grounded in your situation, not a generic playbook.
| Two ICPs, two motions Director+ MS&T / Tech Ops and Director/VP Quality Control | Tech Ops buyers care about catching mismatches pre-execution — before tech transfer drift becomes deviation work. QC buyers are drowning in document review with external analytics partners. Two pains, one platform, two message tracks. |
| Market validation 70%+ of pharma manufacturing still runs on paper | Your own 73-company sample confirms it. Executive teams talk Pharma 4.0; the floor still reconciles batch records by hand. The disconnect is your wedge. |
| Founder-led GTM One commercial customer closed, second in motion, 2-person commercial team | You can close once you're in the room. The constraint is getting Director+ in the room, at volume, without burning founder time on lead-gen scaffolding. |
| Build philosophy Purpose-built AI platform for regulated manufacturing, not assembled from off-the-shelf SaaS | You're building a serious product with engineering discipline. Your commercial layer deserves the same level of intentionality — built custom, built to last, built to grow. |
| Today and tomorrow Biotech and pharma manufacturing first. Food & bev, chemicals, devices next. | Your vision spans regulated industries beyond biotech. The commercial system we build for you is designed for exactly that — biotech today, configured for adjacent verticals when you're ready. The foundation scales with you. |
You need a partner who understands the language, the buyers, and the long sales cycles in biotech — not a generic agency learning your space on your dime. Here's what we bring to the table and why it matters for Trell right now.
MS&T, tech transfer, process development, PPQ readiness, deviation remediation — we know these pain points because we've sold into these roles for 15+ years across life-science enterprise sales. No ramp-up time translating your value prop.
We don't run one-off campaigns. We build you a complete infrastructure — database, dashboard, outreach engine, intelligence layer — that you own outright. The system compounds over time and grows with Trell into new markets.
Karpathy-method AI-assisted development. Modular, well-documented, regression-tested. Supabase backend, GitHub-managed frontend. Every component is standardized so your team (or ours) can extend it without a rewrite.
Brian Elbert — 15 years in life-science enterprise sales (ADP, Smith & Nephew, Terumo BCT, Bionomous). The system was designed by someone who sat in the same seats your buyers sit in.
John Chang from Science2Sales serves as your dedicated single point of contact — weekly calls, strategy sessions, front-end execution. Brian builds the backend system and is available throughout. You get hands-on operator support, not a slide deck and a handoff.
The system we build for biotech is the same system that expands into food & bev, chemicals, and devices. New ICP layer, new personas, same engine. Your growth path is built in from day one.
Generic agencies hand you ZoomInfo exports. We hand you a pre-classified life-sciences intelligence layer with modality, clinical phase, funding stage, and trigger signals already mapped. Here's what's live in the system today.
These are companies in BC's database today, pre-classified, ready to filter into a Trell-tuned target universe in Week 1. No data-vendor purchase. No 6-week list-build.
BC's real-time intelligence layer watches for events that create buying urgency in Trell's ICP. We surface these as outreach triggers, not as background news.
Process description, batch record, and execution package mismatches. Your core wedge — flagged from press releases, hiring patterns, and trial-site activations.
Companies preparing process performance qualification and commercial launch. Funding-stage and clinical-stage cuts identify the right window for Trell.
Facility build-outs, CMO additions, manufacturing partnerships. Every new operating environment is unreconciled evidence waiting to happen.
Multi-resource document review at scale — the second Trell ICP. Surfaced from hiring patterns, vendor changes, and quality leadership transitions.
Warning letters, recall notices, and public deviation events. Acute pain windows where Trell's evidence-package model is provably valuable.
706 CDMOs classified by modality and capacity. We map sponsor-CDMO relationships so Trell can sell into both sides of the transfer.
Director+ MS&T and Director/VP Quality Control are your stated entry points. To maximize foot-in-door velocity, we layer in adjacent buying personas inside the same account — different angles, same target organization, multi-threaded coverage.
Owns process descriptions, tech transfers, batch record execution. Bleeds margin every time site evidence drifts from sponsor standards. Reviews deviations after the damage is done.
Runs document review and external analytics oversight. Stacks expensive reviewers on top of third-party analytics partners. Volume scales linearly with cost.
Owns process design and characterization. Pain: keeping process descriptions, methods, and specs aligned as the platform scales. Champion-style buyer for evidence-package model.
Capital allocator for plant-floor systems. Pain: justifying any new tool against MES/EBR/QMS investments already made. Wants ROI in margin terms, not features.
Owns PPQ readiness, CPV programs, validation lifecycle. Pain: assembling trend-ready datasets from fragmented source records. Direct fit for Trell's CPV-readiness output.
Sells manufacturing capacity to sponsors. Pain: winning tech transfer business when sponsor evidence is messy. Trell becomes a competitive differentiator they can offer clients.
Owns audit posture and regulatory risk. Pain: defending evidence trails to FDA/EMA inspectors. Champion-level buyer when deviations or warning letters create board-level urgency.
Owns Pharma 4.0 modernization. Pain: integrating new tools without ripping out MES/EBR/EDMS. Trell sells as a reconciliation layer, not a replacement.
Each persona gets its own message track, cadence, and content angle — so a single account can be approached through three or four doors in parallel without crossing wires. That's how 90 days produces 15–25 qualified Director+ conversations instead of three.
We build a complete commercial system on a production-grade stack: Supabase backend, GitHub-managed frontend, custom intelligence layer, multi-channel outreach engine. Built using Karpathy-method AI-assisted development — standardized patterns, modular, regression-tested. Ready for vertical and horizontal expansion without a rebuild.
Building this yourself would require sourcing, configuring, and integrating each of these tools independently — and the subscription costs alone approach the monthly investment. We bring all of it, configured and operational from week one.
Sales Navigator · Clay · PhantomBuster
Gemini · Claude Code · GPT
Supabase · GitHub · Lovable
Brave Search · Firecrawl
HeyReach · EmailBison
ZapMail · EmailMelt by Botson
Miller Heiman · SSO Matrix
Your DB · Your Repo · Your Data
Top-level subscriptions across all tools. Multiple premium API credits. You own the database, the repo, the dashboard, the playbooks. We operate it. Take it independent any time — or we keep running it. Your call.
Month 1 we build the system. Month 2 we light it up. Month 3 we tune what works and scale what's hitting. By Month 4 you're operating — or we're operating it for you.
Kickoff workshop. ICP definition (both Tech Ops and QC tracks). Persona mapping across the 8 buyer roles. Supabase spoke deployed. GitHub repo scaffolded. Initial target-account universe filtered from the 17K-account base. Trigger-signal config tuned for your wedge (tech transfer, PPQ, facility expansion, QC review volume).
Custom React dashboard deployed. EmailBison + HeyReach campaigns live across both ICPs with persona-specific message tracks. Content Studio activated for LinkedIn thought-leadership posts in your voice. Weekly performance metrics flowing. Target: first qualified Director+ conversations booked.
A/B test message tracks per persona. Refine trigger detection based on what's converting. Expand content cadence. Add expansion personas (CMC, VP Mfg Ops, Validation, CDMO BD) once core ICPs are firing. Miller Heiman Gold Sheets populated for active accounts. Pipeline velocity baseline established.
Expand account universe based on what's working. Multi-thread accounts across 3+ personas. Weekly strategic briefings — pipeline status, deal velocity, where to press. Target: 15–25 qualified Director+ conversations completed, 3–5 active opportunities, 1–2 toward paid pilot.
Month-to-month. Stay managed (we operate), move to enhanced (we operate, your team co-runs), or go independent (you operate, we advise). Platform Evolution path is built in. No lock-in, ever.
Once the system is operating in biotech, expanding to food & beverage manufacturing (FSMA-driven), specialty chemicals (REACH, ISO 9001), and medical device manufacturing (ISO 13485) is a configuration change, not a new platform. Same Supabase backend. Same React dashboard. Same outreach engine. New ICP layer, new persona profiles, new data sources tuned to the vertical.
The architecture we ship in Month 1 is designed for this from day one — so when Trell is ready to move into adjacent regulated industries, the commercial system moves with you. No rebuild. No re-platforming. Configuration, not construction.
John Chang from Science2Sales serves as your dedicated single point of contact throughout the engagement. Weekly calls, strategy sessions, hands-on front-end execution — John works directly with you and the Trell team to educate, adjust, strategize, and execute the system alignment. Brian Elbert is building the custom backend system behind the scenes and is available throughout the engagement, but the combination of a dedicated execution contact plus a purpose-built backend system is what makes this offering comprehensive.
Cold calling is available as an additional package through Science2Sales. Anis and John offer cold-calling-as-a-service with biotech fluency — cold dials, qualification, meeting booking. If you opt in, BioCreative builds the context and tracking layer underneath: pre-call dossiers, call scripts from account intelligence, post-call logging back into the pipeline, and outcome attribution wired into the same framework. The cold-calling motion plugs into the system; it doesn't sit beside it.
Cold calling is a separate scope priced by Science2Sales — not included in the $7,500/month package. The system support layer for cold calling is included in BC's package if you choose to activate it.
Direct numbers. No tiered-pricing maze. One flat rate for the complete commercial system build and operation.
The complete BioCreative Launch package — build, activate, optimize over 3 months. Exclusively focused on life sciences and biotech during this engagement, building the foundation that scales into adjacent verticals when you're ready.
Month-to-month after Month 3. No long-term lock-in. Full data export anytime. The foundation built during these three months supports future expansion — months 4+ can shift investment, market focus, or path based on what we learn together.
Cold calling via Science2Sales is a separate, additional offering — not included in this package. The system support layer for cold calling is included if you choose to activate it.
Tyler — appreciated the conversation on Monday and the candor about where Trell is and where it's going. This document is the offering we're prepared to put on the table for the first three months, with the architecture and methodology alignment I think makes us the right partner now and as Trell expands.
Please let us know if there's anything you'd like to dig into further, or any additional information we can prepare before our call next Wednesday. Looking forward to continuing the conversation.